Nasdaq:US$31.78 (-1.13) | HKEX:HK$54.80 (-0.35) | AIM:£5.08 (+0.01)
Announcements
123456789
10
1112
found Documents: 584
London: Wednesday, 22 February 2012: Hutchison MediPharma Limited (“HMP”), an R&D company majority owned by Chi-Med, today announces the initiation of the first-in-human Phase I clinical trial of Volitinib (HMPL-504) in Australia.  Volitinib
Read More
London: Wednesday, 21 December 2011: AstraZeneca and Hutchison MediPharma Limited (“HMP”), an R&D company majority owned by Chi-Med, today announce that they have entered into a global licensing, co-development, and commercialisation agreemen
Read More
London, Friday, 4 November 2011: Hutchison MediPharma Limited (“HMP”), the drug R&D company majority owned by Chi-Med, today announces the initiation of the first-in-human Phase I clinical trial of Epitinib (HMPL-813).  This is the third onc
Read More
London: Tuesday, 1 February 2011: Hutchison MediPharma Limited (“Hutchison MediPharma”), the drug R&D company majority owned by Chi-Med, today announces that it has started the first-in-human Phase I clinical trial of its anti-cancer drug can
Read More
London: Friday, 30 April 2010: Hutchison MediPharma Limited (“Hutchison MediPharma”), the wholly-owned drug R&D subsidiary of Chi-Med, today announces that it has initiated the first-in-human Phase I clinical trial of its anti-cancer drug can
Read More